Abstract
Clofarabine (40 mg/m(2)/day × 5) and high-dose cytosine arabinoside (Ara-C, 1-2 g/m(2)/day × 5) were used in 10 men and 11 women, at a median age of 45 (22-62) years, with refractory (N = 4) and relapsed (N = 17) acute myeloid leukaemia, after a median of 3 (2-5) prior regimens. Grade 4 myelosuppression was observed in all cases, with two patients dying of bacterial sepsis. Nine patients achieved a complete remission. Disease status, number of prior therapies, and cytogenetic aberrations were not associated with the outcome. However, remission was only achieved with Ara-C at 2 g/m(2)/day and not 1 g/m(2)/day (9/15 versus 0/4, P = 0.03).
MeSH terms
-
Adenine Nucleotides / administration & dosage*
-
Adenine Nucleotides / adverse effects
-
Adult
-
Antimetabolites, Antineoplastic / administration & dosage*
-
Antimetabolites, Antineoplastic / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Arabinonucleosides / administration & dosage*
-
Arabinonucleosides / adverse effects
-
Clofarabine
-
Cytarabine / administration & dosage*
-
Cytarabine / adverse effects
-
Female
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / prevention & control*
-
Male
-
Middle Aged
-
Recurrence
-
Remission Induction
-
Treatment Outcome
-
Young Adult
Substances
-
Adenine Nucleotides
-
Antimetabolites, Antineoplastic
-
Arabinonucleosides
-
Cytarabine
-
Clofarabine